Serological Response to Human Endogenous Retrovirus K in Melanoma Patients Correlates with Survival Probability
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
A few years ago, reactivation of human endogenous retrovirus K (HERV-K) proviruses in melanoma was described. The expression of HERV-K proteins induces humoral immune responses. The aim of the present study was to elucidate the prognostic relevance of serological anti-HERV-K reactivity in melanoma patients. In a retrospective study, anti-HERV-K Gag and Env antibodies were detected in 51 of the 312 randomly selected and blinded sera from melanoma patients, but not in any of the 70 sera from healthy controls. Comparing serological HERV-K reactivity with established melanoma markers revealed a significant correlation (p = 0.018, Chi-square test) with the stage of disease classified according to the American Joint Committee on Cancer (AJCC). Anti-HERV-K reactivity was elevated in patients with acrolentiginous/mucosal/uveal melanoma (tumor subtypes developing at sun-protected sites) compared to patients with lentigo/nodular/superficial spreading melanoma (p = 0.011, Chi-square test). Patients with anti-HERV-K antibodies had a significantly decreased disease-specific overall survival (stage I-IV, p < 0.001; stage I-III, p = 0.005, log-rank test). Significantly, multivariate Cox regression analysis including prognostic markers in clinical use (e.g., AJCC stage, T-class, serum level of S100-beta) revealed serological HERV-K reactivity as an independent marker of reduced survival probability (p = 0.027) in melanoma patients with the early stages of the disease (AJCC I-III). This is the first report that the humoral anti-HERV-K immune response may provide additional prognostic information to that of established melanoma markers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Expression of Human Endogenous Retrovirus K in Melanomas and Melanoma Cell Lines
Büscher, K., Trefzer, U., Hofmann, M., Sterry, W., Kurth, R., & Denner, J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2983 · Cited by 249 · cited 1×
“Following up data from previous studies 9,11 the present analysis shows that melanoma patients may not only develop a humoral immune response against HERV-K Env but also against Gag proteins.”
T Cell Responses to Human Endogenous Retroviruses in HIV-1 Infection
Garrison, K. E., Jones, R. B., Meiklejohn, D. A., Anwar, N., Ndhlovu, L. C., Chapman, J. M., Erickson, A. L., Agrawal, A., Spotts, G., Hecht, F. M., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030165 · Cited by 131 · cited 1×
“The fact that HERV-K proteins, which in principle are intrinsic self-antigens, can induce humoral and even cytotoxic T lymphocyte responses 24,25 is a promising indication that such approaches might be successful.”
Cited by
Subramanian, R. P., Wildschutte, J. H., Russo, C., & Coffin, J. M. (2011) · Retrovirology · doi:10.1186/1742-4690-8-90 · Cited by 439
Hohn, O., Hanke, K., & Bannert, N. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00246 · Cited by 196
“showed in 2008 that the immune response of melanoma patients against HERVK gene products correlates negatively with their survival (106).”
BackgroundHuman endogenous retroviruses and cancer
María, G.-C., Paola, I., Niki, K., Mariacarmela, S., Julià, B., & Rafael, R. (2016) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2016.0080 · Cited by 100
Metadata
- Authors
- Hahn, S., Ugurel, S., Hanschmann, K.-M., Strobel, H., Tondera, C., Schadendorf, D., Löwer, J., & Löwer, R.
- Venue
- AIDS Research and Human Retroviruses
- Publisher
- SAGE Publications
- Published
- 2008-05
- Volume
- 24
- Issue
- 5
- Pages
- 717-723
- ISSN
- 0889-2229 (ISSN-L)
- 1931-8405
- OpenAlex
- W2007305510
- Cited by
- 108
- References
- 3
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.